Relationship of antibody to outcome in neonatal herpes simplex virus infections
- PMID: 7216423
- PMCID: PMC551151
- DOI: 10.1128/iai.29.2.532-538.1980
Relationship of antibody to outcome in neonatal herpes simplex virus infections
Abstract
Neutralizing antibody titers to herpes simplex virus type 1 (HSV-1) and HSV-2 were measured at birth in normal infants and uninfected infants of mothers with genital HSV infections during pregnancy and at the onset of infection in 5 infants with mild infections and 11 infants with severe infections. Thirty-eight percent of premature and 29% of term infants had neutralization titers of <1:5. High titers ([unk]1:40) were found in 55% of infants of mothers with primary infections during pregnancy and in 76% of infants of mothers with recurrent infections. The mean titers to HSV-1 and -2 in 5 infected infants with mild infections were 1:56 and 1:65 at the time of onset of infection, whereas the mean titers in 11 infants with severe infections were 1:11 and 1:12. Six natally exposed infants who remained asymptomatic were also studied and had a mean titer to HSV-1 of 1:85 and to HSV-2 of 1:69. Therefore, infants with high titers of transplacentally derived antibody had a more favorable outcome than infants with lower titers. Ninety-five percent of the infants of mothers with recurrent infections had a Rawls index of more than 85, suggesting that the antibody response was to HSV-2. However, low levels of antibody with this type specificity failed to protect four infants from infection with HSV-2. Augmentation of the neutralization titer to HSV-2 by the amount of complement present in cord serum was less than twofold. The study suggests that the quantity of antibody derived transplacentally affects the outcome of infection after natal exposure to herpes simplex virus. Complete neutralization of virus by antibody may occur in some infants, and prolongation of the incubation period and modification of the infection may occur in others.
Similar articles
-
Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections.N Engl J Med. 1987 Jan 29;316(5):240-4. doi: 10.1056/NEJM198701293160503. N Engl J Med. 1987. PMID: 3025727
-
Reasons for the absence of a history of recurrent genital infections in mothers of neonates infected with herpes simplex virus.Pediatrics. 1984 Feb;73(2):188-93. Pediatrics. 1984. PMID: 6538039
-
Type-specific antibodies to herpes simplex virus type 2 (HSV-2) glycoprotein G in pregnant women, infants exposed to maternal HSV-2 infection at delivery, and infants with neonatal herpes.J Infect Dis. 1988 Jan;157(1):164-71. doi: 10.1093/infdis/157.1.164. J Infect Dis. 1988. PMID: 2826604
-
Relationships between maternal immunity to herpes simplex virus and the risk of neonatal herpesvirus infection.Rev Infect Dis. 1991 Nov-Dec;13 Suppl 11:S953-6. doi: 10.1093/clind/13.supplement_11.s953. Rev Infect Dis. 1991. PMID: 1664133 Review.
-
Management of neonatal herpes simplex virus infection.Paediatr Drugs. 2001;3(2):81-90. doi: 10.2165/00128072-200103020-00001. Paediatr Drugs. 2001. PMID: 11269641 Review.
Cited by
-
Toward the rational management of herpes infection in pregnant women and their newborn infants. Infectious Diseases and Immunization Committee, Canadian Paediatric Society.CMAJ. 1992 May 1;146(9):1557-60, 1563-6. CMAJ. 1992. PMID: 1571867 Free PMC article. No abstract available.
-
Impaired neonatal natural killer-cell activity to herpes simplex virus: decreased inhibition of viral replication and altered response to lymphokines.J Clin Immunol. 1986 May;6(3):216-24. doi: 10.1007/BF00918701. J Clin Immunol. 1986. PMID: 3013922
-
Herpes simplex virus infections of women and their offspring: implications for a developed society.Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2441-7. doi: 10.1073/pnas.91.7.2441. Proc Natl Acad Sci U S A. 1994. PMID: 8146137 Free PMC article. Review.
-
Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine.Vaccine. 2020 Nov 3;38(47):7409-7413. doi: 10.1016/j.vaccine.2020.09.079. Epub 2020 Oct 9. Vaccine. 2020. PMID: 33041105 Free PMC article.
-
Guidance on management of asymptomatic neonates born to women with active genital herpes lesions.Pediatrics. 2013 Feb;131(2):e635-46. doi: 10.1542/peds.2012-3216. Epub 2013 Jan 28. Pediatrics. 2013. PMID: 23359576 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical